Anaptys Announces Stock Repurchase Plan
March 24, 2025 09:15 ET | Source: AnaptysBio, Inc. SAN DIEGO, March…
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
February 11, 2025 17:30 ET | Source: AnaptysBio, Inc. SAN DIEGO, Feb.…